Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

437 clinical studies listed.

Filters:

Cervical Cancer

Tundra lists 437 Cervical Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Gender: All

Ages: 18 Years - 130 Years

Updated: 2026-11-20

13 states

Adenocarcinoma (NOS)
Anal Cancer
Bladder Cancer
+24
RECRUITING

NCT05051722

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-11-20

14 states

Endometrial Cancer
Cervical Cancer
Atypical Endometrial Hyperplasia
+3
RECRUITING

NCT07524322

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-20

5 states

Breast Cancer
Ovarian Cancer
Endometrial Cancer
+6
ACTIVE NOT RECRUITING

NCT06677190

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-11-19

1 state

Ovarian Cancer
Ovarian Carcinoma
Endometrial Cancer
+5
ACTIVE NOT RECRUITING

NCT05283330

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

6 states

Cervical Cancer
Breast Cancer
Colon Cancer
+4
RECRUITING

NCT03958240

Deciphering Mechanisms Underlying Cancer Immunogenicity

This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors. The study will be conducted on a population of patients with local and/or metastatic malignant solid tumor and who are followed within a standard of care procedure or clinical trial. Patients with any of the following tumor types may be enrolled in the trial: * Head and neck cancer, * Ovarian cancer, * Cervical cancer, * Pre-invasive CIN III cervical cancer (Cervical Intra-epithelial Neoplasia III cervical cancer), * Other solid tumor types (including glioblastoma, NSCLC (Non-small cell lung cancer), anal cancer) Each tumor type will be considered as an independent cohort. For each included patient, biological specimen (tumor sample, blood samples and ascites samples if applicable) will be collected. Study participation of each patient will be 5 years.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

Head and Neck Cancer
Ovarian Cancer
Cervical Cancer
+4
TERMINATED

NCT05063916

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

This is a Phase 2, single center, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic high grade neuroendocrine cervical cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

1 state

Carcinomas
Cervix Cancer
Cervical Cancer
COMPLETED

NCT05924217

Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France

In France, cervical cancer screening is the subject of a national screening programme organized for all asymptomatic individuals aged 25 to 65 years with a cervix. The latter contributes greatly to the prevention and early treatment of this disease, whose public health challenge is recognized worldwide. One of the objectives of this programme is to reduce inequalities in access. Transgender men, i.e. individuals assigned to the female gender at birth but identifying with the male gender, are concerned by this screening as long as they still have a cervix, according to the same modalities as for cisgender women. However, they are often excluded from health care, including organized screening programs. Gender change in civil status is one of the obstacles. The provision of gynaecological care is sometimes inadequate. The lack of knowledge of health professionals and the problems of discrimination that transgender people may face reduce the chances of having equitable access. This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.

Gender: FEMALE

Ages: 25 Years - 65 Years

Updated: 2026-11-17

Cervical Cancer
Transgender Persons
Health Services for Transgender Persons
RECRUITING

NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-17

6 states

Solid Tumor, Adult
Microsatellite Stable Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
+10
RECRUITING

NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-11-17

105 states

Cervical Cancer
RECRUITING

NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal squamous cell carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, breast, and cervical second-line/third-line (cervical 2L/3L) cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-17

12 states

Advanced Solid Tumor
Melanoma
Head and Neck Cancer
+11
ACTIVE NOT RECRUITING

NCT02653118

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58. Because of the high retention of V503-001 participants from the Nordic countries, and the highly efficient screening and surveillance system there, study V503-021 will evaluate only participants from V503-001 sites in Denmark, Norway, and Sweden. The hypothesis is that V503 vaccine will remain effective for at least 30 years after the start of vaccination.

Gender: FEMALE

Ages: 16 Years - 26 Years

Updated: 2026-11-16

2 states

Cervical Cancer
Vulvar Cancer
Vaginal Cancer
+2
NOT YET RECRUITING

NCT07940361

Ultrashort Echo Time (UTE) MRI for Applicator Reconstruction in Gynaecologic Cancer Brachytherapy

The goal of this clinical study is to learn whether an ultrashort echo time (UTE) MRI scan can show the position of brachytherapy applicators and needles more accurately than standard MRI scans in adults with gynaecologic cancer (cervical, endometrial, or vaginal cancer) who are receiving MRI-guided internal radiotherapy (brachytherapy). The main questions it aims to answer are: * Does UTE MRI locate the applicator and needle tips more accurately than standard T2-weighted (T2W) and proton-density-weighted (PDW) MRI, when compared with CT? * Does UTE MRI show a clearer contrast between the applicator and the surrounding tissue? Researchers will compare applicator positions reconstructed from UTE, T2W, and PDW MRI with CT taken on the same day as the reference standard. They will also check whether differences in applicator reconstruction change the planned radiation dose, and whether image features (radiomics) from UTE MRI before treatment and before brachytherapy help predict cancer recurrence. Participants will: * Receive their usual standard brachytherapy treatment, which is not changed by this study * Have one additional MRI sequence (UTE, about 8 minutes) added to their standard MRI and CT scans at each brachytherapy planning session, with the applicator in place * Have an additional UTE sequence added to their routine MRI before treatment and before brachytherapy * Be followed during routine clinical visits for disease outcomes

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-11-16

1 state

Cervical Cancer
Endometrium Cancer
Vagina Cancer
RECRUITING

NCT07336134

PopSci CHW4CervixHealth

Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients. Phase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a self-collection kit to improve cervical health screening intervention aimed to promote HPV self-collection uptake among screening-eligible and under-screened ethnic minority women in the community.

Gender: FEMALE

Ages: 25 Years - 65 Years

Updated: 2026-11-16

1 state

Cervical Cancer
Hpv
Human Papilloma Virus
+1
COMPLETED

NCT05286034

Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme

This project looks to improve the return rate of HPV self-sampling (HPVss) as well as the management of women HPVss positive.

Gender: FEMALE

Ages: 30 Years - 65 Years

Updated: 2026-11-16

Cervical Cancer Screening
Cervical Cancer
NOT YET RECRUITING

NCT07620795

Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing

Cervical cancer is a highly preventable public health issue that significantly impacts women's quality of life. Although effective screening programs such as Human Papilloma Virus (HPV) testing and Pap-smears are widely available, women's participation in these early detection services often remains limited. The primary barriers to screening attendance include insufficient education, lack of information, negative beliefs, psychosocial or cultural factors, and misconceptions regarding gynecological examinations. To improve screening uptake, health interventions must focus not only on increasing knowledge but also on promoting correct beliefs and positive attitudes toward testing. Web-based health education serves as an effective method to overcome barriers such as cost, transportation difficulties, and geographical limitations, allowing wider access to healthcare guidance. This study aims to evaluate the effects of a specialized web-based educational intervention on women's attitudes and beliefs regarding the HPV test. The research is designed as a randomized controlled trial with a pre-test and post-test design. Participants will be assigned to either an intervention group or a control group. The intervention group will receive structured health education through a dedicated web platform, while the control group will receive routine standard follow-up. Data will be gathered using a specific attitude and belief scale before and after the application to measure the intervention's impact.

Gender: FEMALE

Ages: 18 Years - 60 Years

Updated: 2026-11-16

Cervical Cancer
HPV
RECRUITING

NCT07576842

C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV

The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and/or 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16/18) are not well defined. This prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at Month 6 for repeat evaluation. The study will evaluate feasibility for a future trial by examining recruitment, retention, return for evaluation, and completion of treatment. It will also explore management strategies for women with non-16/18 hrHPV based on extended genotyping and HPV viral load compared to standard of care approaches using visual inspection with acetic acid (VIA).

Gender: FEMALE

Ages: 25 Years - Any

Updated: 2026-11-12

1 state

Human Papillomavirus (HPV)
HPV Associated Cancers
Cervical Cancer
+2
RECRUITING

NCT04555226

The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)

This is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage IIICr of cervical cancer have longer PFS and/or OS with lymph node dissection before CCRT when compared to CCRT.

Gender: FEMALE

Ages: 18 Years - 70 Years

Updated: 2026-11-12

1 state

Cervical Cancer
ACTIVE NOT RECRUITING

NCT05359016

Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique

The goal of this operational research study is to develop, implement and test integrated CCS\&PT and voluntary FP service delivery models to evaluate whether integrated service delivery can optimize uptake and health impact of both services. The study objectives and learning questions are listed below, along with key outcomes that will be measured.

Gender: FEMALE

Ages: 30 Years - 49 Years

Updated: 2026-11-12

1 state

Cervical Cancer
ACTIVE NOT RECRUITING

NCT06411938

A Cervical Cancer Prevention Program in Kenya

Cervical cancer is caused by oncogenic, or "high-risk" (HR) human papillomavirus (HPV), and is the main cause of cancer-related death among Kenyan women. This malignancy is theoretically preventable through a combination of screening of adult women and treating those with cervical premalignancies and vaccination of children and adolescents against HPV infection. However, only 5% of Kenyan women are regularly screened, and only 14% have ever been screened, which in Kenya is done by a method known as Visual Inspection with Acetic Acid (VIA). Possible obstacles to current screening include long travel to clinics, high costs, poor sensitivity and specificity of VIA, the need for extensive training for VIA, variability among providers in their interpretation of VIA, lack of trained personnel, and others. In addition, while safe and effective HPV vaccines have been available for 15 years, very few (\<1%) Kenyan children and adolescents have been vaccinated. Obstacles to vaccination include high costs, poor delivery infrastructure, lack of education, long travel to clinics, and others. The investigators began a community-based program in 2018 to develop a framework for eradication of cervical cancer by screening adult women and vaccinating female children. This program is becoming accepted in the Webuye region of Western Kenya, but there is still a great deal to learn. Going forward, this initiative will be known as the Kenya Mother-Daughter Cervical Cancer Eradication Program, or the Mother-Daughter Program (MDP) for short. The investigators propose a continuation of the MDP that will allow them to accumulate additional data needed to solidify the overall project and to answer additional questions as described below. To accomplish this goal the investigators will first enroll an additional 300 adult women to the program. This will increase the strength of the analysis of HR-HPV testing in detecting premalignant lesions of the cervix, especially in HIV-infected women. Second, the investigators will identify the positive and negative features of the MDP from the viewpoint of both the adult women and the girls enrolled in the program. Third, because anogenital warts (AGWs) may serve as a reservoir for HR-HPV, especially in women living with HIV/AIDS, the investigators will examine the prevalence, HPV type distribution, and treatment of these lesions among adult women participating in the MDP.

Gender: FEMALE

Ages: 9 Years - 55 Years

Updated: 2026-11-10

Cervical Cancer Prevention
Cervical Cancer
ACTIVE NOT RECRUITING

NCT06459180

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-11-09

135 states

Cervical Cancer
RECRUITING

NCT07925307

C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV

The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and/or 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16/18) are not well defined. This prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at Month 6 for repeat evaluation. The study will evaluate feasibility for a future trial by examining recruitment, retention, return for evaluation, and completion of treatment. It will also explore management strategies for women with non-16/18 hrHPV based on extended genotyping and HPV viral load compared to standard of care approaches using visual inspection with acetic acid (VIA).

Gender: FEMALE

Ages: 25 Years - Any

Updated: 2026-11-09

Human Papillomavirus (HPV)
HPV Associated Cancers
Cervical Cancer
+2
RECRUITING

NCT05774561

Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring

This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.

Gender: All

Ages: 18 Years - 99 Years

Updated: 2026-11-05

Cervical Cancer
Cervical Dysplasia
Oropharyngeal Cancer
+1
RECRUITING

NCT06952660

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-11-05

22 states

Cervical Cancer